In this article, we are going to take a look at where Aclarion, Inc. (NASDAQ:ACON) stands against the other AI stocks. As the ...

Dr. Nicholas Theodore to highlight NOCISCAN capabilities combining MR Spectroscopy and augmented intelligence (AI) NOCISCAN is an innovative ...

The Company has secured nearly $20 million in gross proceeds in 2025 ensuring complete funding for its pivotal CLARITY trialCLARITY is a ...

BROOMFIELD, Colo. - Aclarion, Inc. (NASDAQ:ACON, ACONW), a healthcare technology company, announced today it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent ...

Recent Notice of Allowance is for Aclarion’s 24th issued US patent Propionic acid (PA) is a biomarker the literature suggests may be indicative of bacterial infection and pain in an ...

Aclarion, Inc. has announced that Northwestern Medicine will serve as the initial site for its pivotal clinical trial, CLARITY, designed to assess the effectiveness and economic value of Nociscan ...

BROOMFIELD, CO - January 24, 2025 (NEWMEDIAWIRE) - Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a healthcare technology company that is ...

Northwestern Medicine is a global leader in clinical trial research, including spine CLARITY is a randomized study designed to demonstrate Nociscan's ability to improve surgical outcomes while ...

CLARITY is a randomized study designed to demonstrate Nociscan’s ability to improve surgical outcomes while reducing costs for chronic low back pain Nociscan aims to become the gold standard in ...

Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., Feb. 04, 2025 (GLOBE NEWSWIRE ...